1. United Kingdom National Health Service. Available at: https://www.nhs.uk/conditions/atopic-eczema/symptoms/. Accessed 21 July 2020.
  2. American Academy of Allergy Asthma and Immunology. Available at:
    https://www.aaaai.org/conditions-and-treatments/library/allergy-library/eczema-atopic-dermatitis. Accessed 21 July 2020.
  3. Data on file. Pfizer.
  4. National Eczema Association. Available at: https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/. Accessed 21 July 2020.
  5. United Kingdom National Health Service. Available at: https://www.nhs.uk/conditions/atopic-eczema/causes/. Accessed 21 July 2020.
  6. Eichenfield LF, Call RS, Forsha DW, et al. J Am Acad Dermatol. 2017;77(4):641-649.
  7. STAQUISTM (crisaborole) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version November 2019.
  8. Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/2076950rig1s000Approv.pdf. Accessed 4 September 2020.
  9. Paller AS. Tom WL. Lebwohl MG, et al. J Am Acad Dermatol. 2016; 75(3):494-503.
  10. Callender VS, Alexis AF, Stein Gold LF, et al. Am J Clin Dermatol. 2019;20(5):711-723.
  11. Bissonnette R, Pavel AB, Diaz A, et al. J Allergy Clin Immunol. 2019;144(5):1274-1289.
  12. Kaufman MB. P T. 2017;42(2):90-91.
  13. Yosipovitch G, Simpson EL, Tan H, et al. Itch. 2018;3(2):e12.
  14. Eucrisa® (crisaborole) US Prescribing Information. Pfizer Inc: Version March 2020.
  15. Eucrisa® (crisaborole) US Patient Information. Pfizer Inc: Version March 2020.

PP-STA-HKG-0058 April 2021